+1-888-308-5802     
News Contact Us

Engrail Therapeutics acquires biopharma company NeuroCycle Therapeutics

Author : Pankaj Singh | Published Date : 2021-02-04 

Engrail Therapeutics Inc. has reportedly acquired Neurocycle Therapeutics, a firm that specializes in sub-type selective GABA-A modulation. According to reliable sources, the acquisition will boost Engrail’s portfolio in the GABA-A space and offer a robust platform for commencing clinical trials with various assets in 2021.

For those unaware, Engrail Therapeutics was established in 2019 and specializes in forging a new path to reduce the immense burden of nervous system-affecting diseases. To develop and catalyze a diversified portfolio of innovative medicines, the company brings together biological insights with clinically relevant solutions.

Engrail leverages its scalable transaction model to advance assets with established mechanisms and efficiently transfer them from production to commercialization, by using a robust scientific approach to identify the most promising therapies.

Vikram Sudarshan, Ph.D., President, and CEO at Engrail Therapeutics reportedly stated that their flexible transaction model and science-first approach enables them to acquire the best assets with a low-risk path to the market where considerable patients need still exists.

He further added that GABA-A is an authenticated target and modulators of these receptors have a therapeutic impact across various psychiatric and neurological conditions. Currently, they have several sub-type selective GABA-A modulators with strong profiles and expect development, cited trusted sources.

Dr. Sudarshan also mentioned that they are committed to developing a premier patient-centric neuroscience organization, with a growing pipeline through co-development, licensing, and acquisitions. He went on to express that over the next few years, their aim is to develop a diverse neuroscience therapeutics pipeline, and the acquisition of NeuroCycle represents another significant step on this path.

Jed Hubbs, Ph.D., President and CEO at NeuroCycle Therapeutics reportedly stated that given their focus and experience in the GABA-A room, they believe that Engrail is an ideal company to carry the work NeuroCycle began. They are looking forward to seeing them bring new drugs to patients who require them, he added.

Financials related to the deal have not been disclosed so far.

Source Credit –

https://www.businesswire.com/news/home/20210202005294/en/Engrail-Therapeutics-Acquires-NeuroCycle-Therapeutics

 

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Samsung seeks tax incentives from Texas officials to build chip plant

Published Date: 2021-03-05         Author: Pankaj Singh

Samsung, a multinational electronics company, has reportedly submitted paperwork to officials in Texas, in request of a billion dollars in tax incentives. This document has been submitted with an aim to make Austin the future hub for its new chip factory worth $17 billion. As per the documents fi... Read More

Flipkart might buy controlling interest in travel aggregator Cleartrip

Published Date: 2021-03-04         Author: Pankaj Singh

Ecommerce giant Flipkart is reportedly in talks to acquire a controlling share in online travel aggregator Cleartrip, further allowing it to boost its footprint in the highly competitive marketplace. The move by Walmart-owned Flipkart is intended to take on contemporaries such as EaseMyTrip, Book... Read More

Groww likely to reach unicorn status with backing from Tiger Global

Published Date: 2021-03-03         Author: Pankaj Singh

An American hedge fund, Tiger Global Management LLC, is in conversation to lead a USD 100 million funding round of millennials-focused investment app, Groww, valuing the firm at USD 1 billion. Sources close to the matter stated that Tiger Global will contribute about USD 50 million, with the remaini... Read More

© 2021 Fractovia. All Rights Reserved